Health Utilities in Patients with Type 2 Diabetes in Taiwan

Overview

Journal Healthcare (Basel)

Specialty Health Services

Date 2021 Dec 24

PMID 34946402

Citations 2

Authors

Chia-Chia Chen

Jin-Hua Chen

Chien-Lung Chen

Tzu-Jung Lai

Yu Ko

Affiliations

Soon will be listed here.

Abstract

We aimed to measure health utilities in patients with diabetes mellitus (DM) in Taiwan and to estimate the impact of common DM-related complications and adverse effects (AEs) on health utilities. The present study was a cross-sectional survey of DM patients at a metropolitan hospital. Respondents' health-related quality of life (HRQoL) was assessed by the EQ-5D-5L, and ordinary least-squares (OLS) regression was used to estimate the impact of self-reported DM-related complications and AEs on health utilities after controlling for age, gender, and duration of DM. A total of 506 eligible adults with type 2 DM (T2DM) were enrolled. The EQ-5D index values in our study sample ranged from -0.13 to 1, with a mean ± standard deviation of 0.88 ± 0.20. As indicated by the negative regression coefficients, the presence of any complication or AE was associated with lower EQ-5D index values, and the greatest impact on the score was made by amputation (-0.276), followed by stroke (-0.211), and blindness (-0.203). In conclusion, the present study elicited health utilities in patients with T2DM in Taiwan using the EQ-5D-5L. These estimated utility decrements provided essential data for future DM cost-utility analyses that are needed as a result of the increasing prevalence and health expenditures of DM.

Citing Articles

Health state utility values of type 2 diabetes mellitus and related complications: a systematic review and meta-regression.

Wang Y, Xu Y, Shan H, Pan H, Chen J, Yang J Health Qual Life Outcomes. 2024; 22(1):74.

PMID: 39244536 PMC: 11380328. DOI: 10.1186/s12955-024-02288-1.

Health state utility values ranges across varying stages and severity of type 2 diabetes-related complications: A systematic review.

Tan M, Ong S, Mohd Tahir N, Mhd Ali A, Mustafa N PLoS One. 2024; 19(4):e0297589.

PMID: 38574169 PMC: 10994347. DOI: 10.1371/journal.pone.0297589.

References

Klarenbach S, Cameron C, Singh S, Ur E . Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ. 2011; 183(16):E1213-20. PMC: 3216433. DOI: 10.1503/cmaj.110178. View

Trikkalinou A, Papazafiropoulou A, Melidonis A . Type 2 diabetes and quality of life. World J Diabetes. 2017; 8(4):120-129. PMC: 5394731. DOI: 10.4239/wjd.v8.i4.120. View

Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N . Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece. Clin Drug Investig. 2016; 36(8):649-59. DOI: 10.1007/s40261-016-0410-2. View

Kiadaliri A, Najafi B, Mirmalek-Sani M . Quality of life in people with diabetes: a systematic review of studies in Iran. J Diabetes Metab Disord. 2013; 12(1):54. PMC: 7968439. DOI: 10.1186/2251-6581-12-54. View

Pham T, Nguyen T, Truong H, Trinh C, Du H, Ngo T . Effects of Diabetic Complications on Health-Related Quality of Life Impairment in Vietnamese Patients with Type 2 Diabetes. J Diabetes Res. 2020; 2020:4360804. PMC: 7003251. DOI: 10.1155/2020/4360804. View

Coffey J, Brandle M, Zhou H, Marriott D, Burke R, Tabaei B . Valuing health-related quality of life in diabetes. Diabetes Care. 2002; 25(12):2238-43. DOI: 10.2337/diacare.25.12.2238. View

Karami H, Shirvani Shiri M, Rezapour A, Sarvari Mehrabadi R, Afshari S . The association between diabetic complications and health-related quality of life in patients with type 2 diabetes: a cross-sectional study from Iran. Qual Life Res. 2021; 30(7):1963-1974. DOI: 10.1007/s11136-021-02792-7. View

Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J . Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab. 2008; 10 Suppl 1:43-55. DOI: 10.1111/j.1463-1326.2008.00886.x. View

McEwan P, Gordon J, Evans M, Ward T, Bennett H, Bergenheim K . Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration. Med Decis Making. 2015; 35(5):660-70. DOI: 10.1177/0272989X14565821. View

10.

Gu S, Mu Y, Zhai S, Zeng Y, Zhen X, Dong H . Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China. PLoS One. 2016; 11(11):e0165629. PMC: 5091768. DOI: 10.1371/journal.pone.0165629. View

11.

Sabale U, Ekman M, Granstrom O, Bergenheim K, McEwan P . Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes. 2014; 9(1):39-47. DOI: 10.1016/j.pcd.2014.04.007. View

12.

Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K . Estimating an EQ-5D-5L Value Set for China. Value Health. 2017; 20(4):662-669. DOI: 10.1016/j.jval.2016.11.016. View

13.

Hayes A, Arima H, Woodward M, Chalmers J, Poulter N, Hamet P . Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study. Value Health. 2016; 19(1):36-41. DOI: 10.1016/j.jval.2015.10.010. View

14.

Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J . Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2017; 21(2):1-218. PMC: 5292646. DOI: 10.3310/hta21020. View

15.

van Haalen H, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M . Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig. 2013; 34(2):135-46. DOI: 10.1007/s40261-013-0155-0. View

16.

Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K . The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. Diabet Med. 2015; 32(7):890-8. DOI: 10.1111/dme.12772. View

17.

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157:107843. DOI: 10.1016/j.diabres.2019.107843. View

18.

Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K . Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective. BMC Health Serv Res. 2015; 15:496. PMC: 4635987. DOI: 10.1186/s12913-015-1139-y. View

19.

Solli O, Stavem K, Kristiansen I . Health-related quality of life in diabetes: The associations of complications with EQ-5D scores. Health Qual Life Outcomes. 2010; 8:18. PMC: 2829531. DOI: 10.1186/1477-7525-8-18. View

20.

Wong E, Ramos-Goni J, Cheung A, Wong A, Rivero-Arias O . Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong. Patient. 2017; 11(2):235-247. PMC: 5845074. DOI: 10.1007/s40271-017-0278-0. View